Upgrade to SI Premium - Free Trial

Form 3 AC Immune SA For: Mar 18 Filed by: Roberts Christopher James

March 18, 2026 1:09 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Roberts Christopher James
(Last) (First) (Middle)
EPFL INNOVATION PARK, BUILDING B
(Street)
LAUSANNE 1015
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares 155,382 (1)
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (right to buy) (2) 10/02/2029 Common Shares 7,200 5.15 D
Share Option (right to buy) (2) 10/12/2030 Common Shares 7,200 6.3 D
Share Option (right to buy) (2) 10/05/2031 Common Shares 7,200 6.88 D
Share Option (right to buy) (2) 09/30/2032 Common Shares 7,200 2.76 D
Share Option (right to buy) (2) 07/31/2033 Common Shares 29,126 2.32 D
Share Option (right to buy) (3) 12/31/2033 Common Shares 55,215 3.99 D
Share Option (right to buy) (4) 12/31/2034 Common Shares 92,308 2.91 D
Share Option (right to buy) (5) 12/31/2035 Common Shares 89,552 3.03 D
Explanation of Responses:
1. Includes 109,564 common shares underlying outstanding restricted share units.
2. The share option is fully vested.
3. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2024.
4. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2025.
5. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2026.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Matthias Maurer, attorney-in-fact for Christopher James Roberts 03/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

POWER OF ATTORNEY

Categories

SEC Filings